Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.

DOI Web Site 1 Citations

Noboru Yamamoto

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan;
Takashi Seto

Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan;
Makoto Nishio

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;
Koichi Goto

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan;
Isamu Okamoto

Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;
Takeharu Yamanaka

Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan;
Misa Tanaka

Chugai Pharmaceutical Co., Ltd, Tokyo, Japan;
Koji Takahashi

Chugai Pharmaceutical Co., Ltd, Tokyo, Japan;
Masahiro Fukuoka

Izumi Municipal Hospital, Izumi City, Japan;
Nobuyuki Yamamoto

Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan;

Journal

Journal of Clinical Oncology

Journal of Clinical Oncology 36 (15_suppl), 9007-9007, 2018-05-20

American Society of Clinical Oncology (ASCO)

Back to top